Rentschler Biopharma
- 1
- 2
Rentschler Biopharma announces strategic realignment of its global business operations
30 January 2025 – Laupheim, Germany – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations as part of a long-term strategic shift. As part of this realignment, Rentschler Biopharma will withdraw from the field of cell and gene therapy, ceasing...
Rentschler Biopharma announces largest single investment at its headquarters in Germany
Construction of a new buffer media facility in Laupheim Largest investment in the German site; project duration of approx. three years Continuous modernization, automation, and digitalization of the site. 24 October 2024 -- Laupheim, Germany -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products...
Rentschler Biopharma introduces new lentiviral vector manufacturing toolbox for advanced therapies
Expanded service offering client ready at company’s site in Stevenage, UK Offering includes process development and cGMP manufacturing services, as well as complementary in-house analytical and regulatory support for lentiviral vectors 5 September 2024 – Stevenage, UK and Laupheim, Germany – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals,...
Rentschler Biopharma appoints Patrick Meyer as global head BD Sales and Alliance Management
28 May 2024 – Laupheim, Germany; Milford, MA, US; and Stevenage, UK – Rentschler Biopharma SE, a leading global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that Patrick Meyer, PhD, has been promoted to global head BD Sales and Alliance Management within the business development team,...
Rentschler Biopharma appoints Patrick Cushing as VP Operations for US subsidiary
2 May 2024 – Laupheim, Germany; Milford (MA), US; and Stevenage, UK – Rentschler Biopharma SE, a leading global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, today announced that Patrick Cushing, PhD, has been promoted to vice president operations of Rentschler Biopharma, Inc., the company’s US subsidiary, effective 1 May 1 2024. In this...
Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023
Exceptional capabilities in guiding therapies from early-stage development through to market based on over 50 years of biotech experience 6 March 2024 – Laupheim, Germany; Milford, MA, US; and Stevenage, UK – In 2023, the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 55 new drugs, 17 of which...
Senta Brandt and Gerrick Rodrigues appointed to global leadership positions at Rentschler Biopharma
Senta Brandt promoted to global position of Head of Transformation Gerrick Rodrigues promoted to Global Head of IT 6 February 2024 – Laupheim, Germany; Milford, MA, USA; and Stevenage, UK – Rentschler Biopharma SE, a leading contract development and manufacturing organisation (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that Senta Brandt...
Rentschler Biopharma announces major client project for new US facility at Milford, MA Site
State-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) facility slated to open for business next year 20 December 2023 – Laupheim, Germany and Milford, MA, US – Rentschler Biopharma SE, a leading global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, today announced that the company has secured a major client for the new Rentschler Biopharma Manufacturing...
Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board
7 December 2023 – Laupheim, Milford, MA, USA, and Stevenage, UK – Rentschler Biopharma SE, a leading contract development and manufacturing organisation (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs), announced today that Gunnar Voss von Dahlen (54) has been appointed as chief financial officer, effective 1 December 2023. With over 17 years of...
Dr Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma
4 December 2023 – Laupheim, Germany – Rentschler Biopharma SE, a leading contract development and manufacturing organisation (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs), announced today that Dr Günter Stempfer has been appointed Site Head of the company’s facility in Laupheim, Germany, effective 1 December 2023. In this role, he is heading the...
- 1
- 2
Erwin-Rentschler-Str. 21 88471 Laupheim Germany
+49 7392 701-0
